Concerns on the use of Aluminum oxyhydroxide (alum) adjuvants in the vaccines
According to the article by Gherardi, Eidi, CrÃ©peaux, Authier, & Cadusseau (2015) there are concerns about the use of Aluminum oxyhydroxide (alum) asadjuvants in the vaccines the Alum Adjuvants have been found to have a role in the macrophagic myofasciitis (MMF) lesion that was,s detected in a patient with myalgic encephalomyelitis/chronic fatigue/syndrome.
According to the author, MMF revealed that the use of Alum as an adjuvant in the vaccines hurts the people that are supposed to be vaccinated. The unexpected bio-persistence of Alum in the immune cells has been blamed for causing some uncomfortable effects on the lives of the patients that have been vaccinated.
The findings are a result of the immunological experiments that were done. The findings of the experiments are important, meaning that they are not supposed to be ignored in any way. The strength of the experimental model is that the findings are factual; hence, they can be proven. The test is also valid and has a high degree of accuracy. One of the weaknesses are the fact that it is not easy to link the fatigue in the patients with the bio-persistence of alum in the immunological cells.
The implications of the findings may be dire because of the fact that people care about their health. It may lead to several people boycotting some immunization schedules and naming it as harmful. Some people may also associate some of the symptoms that they feel with the vaccine that they received.
The two terms to be defined are bio-persistence and immunological cells. Bio-persistence refers to the tendency of a chemical or an agent remaining in the body of a living organism instead of being broken down. Immunological cells, on the other hand, refer to the cells that are used in fighting pathogens and other antigens in the bodies of human beings.
Gherardi, R. K., Eidi, H., CrÃ©peaux, G., Authier, F. J., & Cadusseau, J. (2015). Biopersistence and Brain Translocation of Aluminum Adjuvants of Vaccines. Frontiers in Neurology, 6. doi:10.3389/fneur.2015.00004